CD20

Investigation Report on the Chinese Rituximab Market to 2022: Enterprise Profiles for Roche and Genentech, and their Sales of Rituximab in China

Retrieved on: 
星期二, 七月 31, 2018
Health, Medicine, Biotechnology, Hoffmann-La Roche, RTT, Rituximab, Immunology, Genentech, CD20, Monoclonal antibody, Ocrelizumab

The "Investigation Report on Chinese Rituximab Market - 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on Chinese Rituximab Market - 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • Rituximab (Roche's trade name: Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997.
  • In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%.
  • By July 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech.